C4 Therapeutics, INC Schedule 13G passive stakes

RA Capital Management, along with affiliated entities and individuals, has reported a beneficial ownership of 9.9% in C4 Therapeutics, Inc. as of June 30, 2026, primarily through warrants and common stock.

Squadron Master Fund LP, along with affiliated entities and individuals, has disclosed beneficial ownership of approximately 6.9% of C4 Therapeutics, Inc. common stock.

Morgan Stanley entities have reported a decrease in their beneficial ownership of C4 Therapeutics, Inc. common stock, now holding less than 5% collectively.

BlackRock, Inc. has reported a beneficial ownership of 6.9% of C4 Therapeutics, Inc.'s common stock as of June 30, 2026.

Squadron Master Fund LP, along with affiliated entities and individuals, has disclosed a beneficial ownership of 5,550,000 shares, representing 5.0% of the outstanding common stock of C4 Therapeutics, Inc.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have disclosed a beneficial ownership of 0.2% in C4 Therapeutics, Inc. common stock.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of C4 Therapeutics, Inc. common stock, primarily through warrants.

Wasatch Advisors LP has filed an amendment disclosing a reduction in its beneficial ownership of C4 Therapeutics Inc to 4.7%.

Lynx1 Capital Management LP and Weston Nichols have disclosed a 7.3% beneficial ownership stake in C4 Therapeutics, holding 7,098,133 shares.

Soleus Capital Management and affiliated entities report a significant beneficial ownership stake of 9.99% in C4 Therapeutics, Inc., including warrants.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed a combined beneficial ownership of 9.3% in C4 Therapeutics, Inc. common stock.

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed an amended Schedule 13G, reporting a combined beneficial ownership of 7.3% in C4 Therapeutics, Inc. as of September 30, 2025.

Wasatch Advisors LP has reported a 6.8% beneficial ownership stake in C4 Therapeutics Inc., holding 4,852,741 common shares.

Bain Capital Life Sciences entities disclose a collective 7.4% beneficial ownership in C4 Therapeutics, including common stock and warrants.

RA Capital Management and its affiliates reported a 9.9% beneficial ownership stake in C4 Therapeutics, Inc., totaling 9,441,256 shares.

Point72 Asset Management, along with affiliates and Steven A. Cohen, reported a 9.9% beneficial ownership stake in C4 Therapeutics, including warrants.

Morgan Stanley has disclosed a 6.7% beneficial ownership stake in C4 Therapeutics, Inc. common stock.

BlackRock, Inc. has reduced its beneficial ownership in C4 Therapeutics, Inc. to 2.5% of the common stock, as disclosed in an amended Schedule 13G filing.

OrbiMed Advisors LLC and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, detailing their beneficial ownership of 9.7% of C4 Therapeutics, Inc.'s common stock as of March 31, 2025.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of C4 Therapeutics, Inc. as of March 31, 2025.

Wasatch Advisors LP has filed an amended Schedule 13G, revealing a 10.5% beneficial ownership stake in C4 Therapeutics, Inc., as of April 30, 2025.

Morgan Stanley has filed a Schedule 13G, reporting a 5.4% beneficial ownership stake in C4 Therapeutics, Inc. as of December 31, 2024.